UCB SA (EBR:UCB)

Market Cap	50.46B
Revenue (ttm)	6.85B
Net Income (ttm)	1.33B
Shares Out	190.00M
EPS (ttm)	6.87
PE Ratio	38.68
Forward PE	29.13
Dividend	1.39 (0.52%)
Ex-Dividend Date	Apr 25, 2025

Volume	243,249
Average Volume	175,047
Open	262.00
Previous Close	259.50
Day's Range	261.00 - 268.40
52-Week Range	129.35 - 268.40
Beta	0.25
RSI	70.49
Earnings Date	Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1925
• Employees: 9,378
• Stock Exchange: Euronext Brussels
• Ticker Symbol: UCB

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.